CF:XRX XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol XRTX.

This company has cross-listed shares that trade in the U.S. as the symbol XRTX.

4.80 CAD
As of 11/03/2021


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  01/01/1900
Stock exchange:    Canadian Securities Excha
Exchange country:   Canada
Market cap:   58,995,364 CAD
Current dividend yield:   0.00%
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy